Employing fit-for-purpose biomarkers in the earliest phases of drug development can advance rational clinical development of drug candidates. Identifying the right biomarker(s) for this task is crucial, especially in mitochondrial disorders—diseases characterized by substantial heterogeneity, both ...
Page:
of
15